NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jul 2

PMID 34205110

Citations 2

Authors

Thomas Geyer

Johannes Rubenthaler

Marianna Alunni-Fabbroni

Regina Schinner

Sabine Weber

Julia Mayerle

Eric Schiffer

Sebastian Hockner

Peter Malfertheiner

Jens Ricke

Affiliations

Soon will be listed here.

Abstract

Background: This exploratory study aimed to evaluate lipidomic and metabolomic profiles in patients with early and advanced HCCs and to investigate whether certain metabolic parameters may predict the overall survival in these patients.

Methods: A total of 60 patients from the prospective, randomized-controlled, multicenter phase II SORAMIC trial were included in this substudy; among them were 30 patients with an early HCC who underwent radiofrequency ablation combined with sorafenib or a placebo and 30 patients with an advanced HCC who were treated with a selective internal radiation therapy (SIRT) plus sorafenib vs. sorafenib alone. The blood serum of these patients was analyzed using a standardized nuclear magnetic resonance (NMR) platform. All tested metabolites were correlated with the overall survival.

Results: The overall survival (OS) was significantly higher in patients with an early HCC (median OS: 34.0 months) compared with patients with an advanced HCC (median OS: 12.0 months) ( < 0.0001). Patients with high serum concentrations of myo-inositol (MI) had a higher overall survival compared with patients with low concentrations (21.6 vs. 13.8 months) with a Pearson correlation coefficient of 0.331 ( = 0.011). Patients with high serum concentrations of dimethylamine had a higher overall survival compared with patients with low concentrations (25.1 vs. 19.7 months) with a Pearson correlation coefficient of 0.279 ( = 0.034). High concentrations of total cholesterol, LDL-cholesterol and LDL particles (LDL-P) were associated with a decreased overall survival.

Conclusions: NMR-based lipidomic and metabolomic profiling has the potential to identify individual metabolite biomarkers that predict the outcome of patients with an HCC exposed to non-invasive therapeutic management.

Citing Articles

Tian J, Meng J, Yang Z, Song L, Jiang X, Zou J Front Immunol. 2024; 15:1411161.

PMID: 38799437 PMC: 11116790. DOI: 10.3389/fimmu.2024.1411161.

Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine.

Wu X, Wang Z, Luo L, Shu D, Wang K Front Med Technol. 2023; 4:1065506.

PMID: 36688143 PMC: 9845953. DOI: 10.3389/fmedt.2022.1065506.

References

Schettler V, Muellendorff F, Schettler E, Platzer C, Norkauer S, Julius U . NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study). Ther Apher Dial. 2019; 23(5):467-473. DOI: 10.1111/1744-9987.12792. View

Mora S, Buring J, Ridker P . Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2013; 129(5):553-61. PMC: 4501252. DOI: 10.1161/CIRCULATIONAHA.113.005873. View

Trompet S, Jukema J, Katan M, Blauw G, Sattar N, Buckley B . Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol. 2009; 170(11):1415-21. DOI: 10.1093/aje/kwp294. View

Alcazar-Roman A, Wente S . Inositol polyphosphates: a new frontier for regulating gene expression. Chromosoma. 2007; 117(1):1-13. DOI: 10.1007/s00412-007-0126-4. View

Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E . A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2006; 15(8):1526-31. DOI: 10.1158/1055-9965.EPI-06-0128. View

Xuan C, Tian Q, Li H, Zhang B, He G, Lun L . Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants. Eur J Prev Cardiol. 2015; 23(5):502-10. DOI: 10.1177/2047487315586094. View

Banas M, Neumann S, Eiglsperger J, Schiffer E, Putz F, Reichelt-Wurm S . Identification of a urine metabolite constellation characteristic for kidney allograft rejection. Metabolomics. 2019; 14(9):116. PMC: 6133122. DOI: 10.1007/s11306-018-1419-8. View

Baumstark D, Kremer W, Boettcher A, Schreier C, Sander P, Schmitz G . H NMR spectroscopy quantifies visibility of lipoproteins, subclasses, and lipids at varied temperatures and pressures. J Lipid Res. 2019; 60(9):1516-1534. PMC: 6718440. DOI: 10.1194/jlr.M092643. View

Jiang S, Weng D, Jiang L, Zhang Y, Pan K, Pan Q . The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. J Cancer. 2016; 7(6):626-32. PMC: 4829548. DOI: 10.7150/jca.13837. View

10.

Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjorge T, Borena W . Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One. 2013; 8(1):e54242. PMC: 3553083. DOI: 10.1371/journal.pone.0054242. View

11.

Vucenik I, Shamsuddin A . Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr. 2003; 133(11 Suppl 1):3778S-3784S. DOI: 10.1093/jn/133.11.3778S. View

12.

Suzuki H, Kohjima M, Tanaka M, Goya T, Itoh S, Yoshizumi T . Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma. Can J Gastroenterol Hepatol. 2021; 2021:8813410. PMC: 7910064. DOI: 10.1155/2021/8813410. View

13.

Banas M, Neumann S, Pagel P, Putz F, Kramer B, Bohmig G . A urinary metabolite constellation to detect acute rejection in kidney allografts. EBioMedicine. 2019; 48:505-512. PMC: 6838399. DOI: 10.1016/j.ebiom.2019.10.007. View

14.

Liu Q, Luo Q, Halim A, Song G . Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer. Cancer Lett. 2017; 401:39-45. DOI: 10.1016/j.canlet.2017.05.002. View

15.

Dinicola S, Fabrizi G, Masiello M, Proietti S, Palombo A, Minini M . Inositol induces mesenchymal-epithelial reversion in breast cancer cells through cytoskeleton rearrangement. Exp Cell Res. 2016; 345(1):37-50. DOI: 10.1016/j.yexcr.2016.05.007. View

16.

Ricke J, Klumpen H, Amthauer H, Bargellini I, Bartenstein P, De Toni E . Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019; 71(6):1164-1174. DOI: 10.1016/j.jhep.2019.08.006. View

17.

SAUER L, Dauchy R, Blask D . Dietary linoleic acid intake controls the arterial blood plasma concentration and the rates of growth and linoleic acid uptake and metabolism in hepatoma 7288CTC in Buffalo rats. J Nutr. 1997; 127(7):1412-21. DOI: 10.1093/jn/127.7.1412. View

18.

Nderitu P, Bosco C, Garmo H, Holmberg L, Malmstrom H, Hammar N . The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort. Int J Cancer. 2017; 141(6):1148-1160. DOI: 10.1002/ijc.30818. View

19.

Unfer V, Facchinetti F, Orru B, Giordani B, Nestler J . Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017; 6(8):647-658. PMC: 5655679. DOI: 10.1530/EC-17-0243. View

20.

Stratmann B, Krepak Y, Schiffer E, Jarick I, Hauber M, Lee-Barkey Y . Beneficial Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients with Type 2 Diabetes Mellitus: Analysis of Responders and Non-Responders. Horm Metab Res. 2016; 48(10):630-637. DOI: 10.1055/s-0042-115175. View